{"id":14383,"date":"2021-07-13T12:56:08","date_gmt":"2021-07-13T09:56:08","guid":{"rendered":"https:\/\/ufuture.com\/?p=14383"},"modified":"2021-07-13T12:56:08","modified_gmt":"2021-07-13T09:56:08","slug":"biopharma-plans-to-invest-18-million-in-production-in-2021","status":"publish","type":"post","link":"https:\/\/ufuture.com\/en\/biopharma-plans-to-invest-18-million-in-production-in-2021\/","title":{"rendered":"Biopharma plans to invest $18 million in production in 2021"},"content":{"rendered":"<p><a href=\"https:\/\/ufuture.com\/en\/our-companies\/biofarma\/\">The pharmaceutical company Biopharma<\/a>, whose strategic investor is the holding company UFuture, plans to complete the construction of a new office and laboratory complex in Bila Tserkva and 4 plasma centers by the end of the year, investing $18 million in 2021.<\/p>\n<p>Currently, Biopharma is actively investing in the development of a network of donor centers in different cities of Ukraine \u2014 in 2020 the company was engaged in the production of immunoglobulins and conducted clinical studies that showed that the use of immunoglobulins Biopharma increased the production of immunoglobulins by 60% and increased its share of the domestic market compared to exports to 80%.<\/p>\n<p>According to Kostyantyn Efymenko, President of the pharmaceutical company Biopharma, in the future, the ratio of domestic sales to exports will be 60% to 40%. According to him, by 2025 the company will process approximately 600,000 liters of plasma per year to provide Ukrainian citizens with plasma-based drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pharmaceutical company Biopharma, whose strategic investor is the holding company UFuture, plans to complete the construction of a new&#8230;<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"single-new.php","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/14383"}],"collection":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/comments?post=14383"}],"version-history":[{"count":1,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/14383\/revisions"}],"predecessor-version":[{"id":14384,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/14383\/revisions\/14384"}],"wp:attachment":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/media?parent=14383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/categories?post=14383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/tags?post=14383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}